F. Hoffmann-La Roche AG

• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly… Ended
  2023-507196-22-00 Phase III 4 countries
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended
  2023-507131-38-00 Phase III 6 countries RANIBIZUMAB
• A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII… Ended
  2023-505747-40-00 Phase IV 4 countries EMICIZUMAB
• A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A… Ended
  2023-506761-65-00 Phase II/III 9 countries
• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s… Ended
  2023-503868-16-00 Phase III 7 countries ATEZOLIZUMAB; LURBINECTEDIN
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended
  2023-506516-40-00 Phase III 17 countries DIMENHYDRINATE; FINGOLIMOD; METHYLPREDNISOLONE SODIUM SUCCINATE; OCRELIZUMAB
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis Ended
  2022-502619-13-00 Phase II 3 countries
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended
  2023-506986-74-00 Phase I/II 2 countries MOSUNETUZUMAB; POLATUZUMAB VEDOTIN; RITUXIMAB; TOCILIZUMAB
• A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len… Ended
  2023-505807-21-00 Phase III 5 countries
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended
  2023-504774-38-00 Phase III 5 countries OBINUTUZUMAB
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended
  2023-507130-24-00 Phase III 6 countries RANIBIZUMAB
• A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended
  2023-507494-18-00 Phase III 10 countries CRIZOTINIB; ENTRECTINIB
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended
  2023-508194-89-00 Phase II 5 countries ABEMACICLIB; ATEZOLIZUMAB; BEVACIZUMAB; COBIMETINIB; CYCLOPHOSPHAMIDE MONOHYDRAT…
• A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended
  2023-505089-27-00 Phase III 7 countries CROVALIMAB
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended
  2023-507132-21-00 Phase II/III 6 countries PRASINEZUMAB
• A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended
  2023-503229-21-00 Phase III 12 countries ATEZOLIZUMAB; LENVATINIB; SORAFENIB
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended
  2023-506525-11-00 Phase III 4 countries OBINUTUZUMAB; TACROLIMUS
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended
  2023-503568-18-00 Phase III 14 countries ATEZOLIZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
• A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog… Ended
  2023-506498-36-00 Phase III 9 countries CROVALIMAB
• A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination w… Ended
  2023-506899-27-00 Phase III 6 countries GLOFITAMAB; OBINUTUZUMAB; RITUXIMAB; TOCILIZUMAB
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo… Ended
  2023-506526-37-00 Phase III 13 countries CROVALIMAB
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended
  2023-507418-28-00 Phase II 8 countries ALECTINIB; ATEZOLIZUMAB; BELVARAFENIB; CAMONSERTIB; DIVARASIB; ENTRECTINIB; INAV…
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12… Ended
  2023-505964-13-00 Phase III 6 countries EMICIZUMAB
• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended
  2022-502705-15-00 Phase III 9 countries ATEZOLIZUMAB

Showing 97–120 of 221 trials